AMPEL BioSolutions is a leading brand in the field of personalized precision medicine for autoimmune and inflammatory diseases. They offer the AMPEL Genomic Platform (AGP®), which supports genomic blood and biopsy tests for patients. This platform utilizes RNA analytics, bioinformatics, and machine learning/AI to provide dynamic disease management.

With the AGP® platform, patients can identify molecular pathways, evaluate immune status, predict flares, and explore drug options. AMPEL is constantly developing new products to cater to various diseases. Currently, their pipeline includes LuGENE, DermaGENE, and WellGENE, with more in development for lupus, dermatology, cardiology, arthritis, nephrology, fibromyalgia, infection, and oncology.

They have a robust database with 95% coverage of all known genes and rich clinical information, making it the largest resource for lupus. AMPEL BioSolutions has achieved significant recognition in the industry, supported by 35+ technology patents and validation from over 20 pharma customers. Their co-founders, Amrie Grammer and Peter Lipsky, are esteemed scientists and entrepreneurs.

With a focus on personalized precision medicine, AMPEL is dedicated to reducing uncertainty in clinical care using genomic data. For more information, reach out to them at info@ampel. org or call (434) 296-AMPL (2675)